Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes
20141.5k citationsAndré Scheen, Nicolas Paquot et al.profile →
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
20051.2k citationsLuc F. Van Gaal, André Scheen et al.profile →
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study
2006558 citationsAndré Scheen, Luc F. Van Gaal et al.profile →
This map shows the geographic impact of André Scheen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by André Scheen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites André Scheen more than expected).
This network shows the impact of papers produced by André Scheen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by André Scheen. The network helps show where André Scheen may publish in the future.
Co-authorship network of co-authors of André Scheen
This figure shows the co-authorship network connecting the top 25 collaborators of André Scheen.
A scholar is included among the top collaborators of André Scheen based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with André Scheen. André Scheen is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Scheen, André. (2015). Comment je traite ... A propos du positionnement des inhibiteurs de la DPP-4 (gliptines) dans le traitement du diabète de type 2. Open Repository and Bibliography (University of Liège).1 indexed citations
Descamps, Olivier, Guy De Backer, Lieven Annemans, Erik Muls, & André Scheen. (2012). [New European guidelines for the management of dyslipidaemia in cardiovascular prevention].. PubMed. 67(3). 118–27.1 indexed citations
10.
Scheen, André, et al.. (2011). Inhibiteurs du cotransporteur du glucose SGLT rénal pour traiter le diabète de type 2. Open Repository and Bibliography (University of Liège).2 indexed citations
Keymeulen, Bart, et al.. (2009). Anticorps monoclonaux en diabétologie: jusqu'au bout du rêve?. VUBIR (Vrije Universiteit Brussel).
13.
Scheen, André & Jean-Marie Krzesinski. (2008). ONTARGET: similar protection of telmisartan and ramipril and lack of benefit of combined therapy in patients at high risk for vascular events. Open Repository and Bibliography (University of Liège).4 indexed citations
14.
Paquot, Nicolas, Hans Vandenberghe, André Scheen, Christophe De Block, & L. Van Gaal. (2008). Glycaemic and blood pressure control seems harder to improve than lipid control in type 2 diabetic patients: comparison of two surveys over 5 years in Belgium.. Open Repository and Bibliography (University of Liège).1 indexed citations
15.
Binder, Marc D., et al.. (2006). Statin therapy among schizophrenia patients with dyslipidemia. Open Repository and Bibliography (University of Liège).1 indexed citations
16.
Schmitz, O., B Charbonnel, & André Scheen. (2006). Pioglitazone reduces insulin requirements and improves glycaemic control in insulin-treated patients with type 2 diabetes: results from PROactive. Open Repository and Bibliography (University of Liège).5 indexed citations
17.
Scheen, André, et al.. (2004). Influence of blood glucose control on the progression of cardiac autonomic neuropathy in Type 1 diabetes.. Open Repository and Bibliography (University of Liège).1 indexed citations
18.
Scheen, André, Bernard Jandrain, Nicolas Paquot, Michel Letiexhe, & Philippe Lefèbvre. (2001). Contrôle pharmacologique de l’hyperglycémie postprandiale. Open Repository and Bibliography (University of Liège).1 indexed citations
19.
Scheen, André, Nicolas Paquot, M. Castillo, & Patrick Lefèbvre. (1996). Traitement du diabète de type II insulino-requérant: intérêt potentiel de l'association insuline-antidiabétiques oraux. Open Repository and Bibliography (University of Liège).
20.
Scheen, André, et al.. (1988). Les cures de jeûne modifié, protidique ou glucido-protidique, dans le traitement de l'obésité morbide.. Open Repository and Bibliography (University of Liège).2 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.